ELAB PMGC Holdings Inc. logo

ELAB PMGC Holdings Inc.

Healthcare
$1.78+7.23%ClosedMarket Cap: $3.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.06

P/S

2.71

EV/EBITDA

0.33

DCF Value

$-588.76

FCF Yield

-230.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

12.7%

Operating Margin

-746.6%

Net Margin

-873.1%

ROE

-117.0%

ROA

-42.7%

ROIC

-46.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$682.0K$-5.0M$
Q1 null$682.0K$-5.0M$
Q4 null$304.1K$-3.0M$
FY null$590.1K$-7.7M$

Trading Activity

Insider Trades

View All
Parry Jeffreydirector
SellTue Feb 10
Parry Jeffreydirector
SellTue Feb 10
Parry Jeffreydirector
SellTue Feb 10
Daley Julianadirector
SellMon Feb 09
Daley Julianadirector
SellMon Feb 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

-0.28

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Peers